Galmed Pharmaceuticals announced an agreement to acquire Colospan, a medical device company with a CE-marked intraluminal bypass device designed to reduce complications in colorectal surgery. The CG-100 device has FDA Breakthrough Device Designation and is in a pivotal U.S. clinical trial, aiming to reduce the need for diverting stomas that impact patient quality of life. The acquisition, expected to close in Q2 2026, will position Galmed as a GI-focused medtech and biopharmaceutical platform, with plans to launch the device commercially in Europe by H2 2026 starting in Germany, Austria, and Switzerland. This move accelerates Galmed's strategy to offer innovative solutions for colorectal surgery complications and expand its clinical and commercial capabilities.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
Ethereum's price rose about 11% over the past week to around $1,920, outperforming major cryptocurrencies like Bitcoin and Solana. This rally is fueled by $96 million inflows into U.S. spot Ether ETFs early in the week, with BlackRock's ETHA product ...
The XRP Ledger has surpassed 8 million activated accounts, marking steady growth since March 2026. However, daily active addresses have declined to a 2026 low of 25,350, indicating less frequent user engagement despite overall adoption. XRP's price f...
